Stem Cell Technologies & Biomarkers
MISSION
SCT&B (Stem Cell Technologies & Biomarkers) is a Canadian biotechnology company founded in 2013.
The company develops innovative cellular technologies, biomarkers and biological navigation platforms for regenerative medicine, precision medicine and translational research.
Our mission is to transform invisible disease into actionable clinical information through innovative biological technologies that support disease detection, monitoring and clinical decision-making.
Today, SCT&B is advancing ARISTEM GPS™, a novel biological navigation platform designed to investigate how naturally autoguided cellular systems may help locate pathological tissues and improve clinical insight.
We collaborate with academic, clinical and industry partners to accelerate the validation and translation of next-generation biotechnology innovations.
SERVICES & TECHNOLOGY PLATFORMS
SCT&B develops innovative biotechnology platforms at the intersection of cellular technologies, biomarkers and precision medicine.
Our focus areas include:
• ARISTEM GPS™
• Biological Navigation
• Cellular Technologies
• Biomarker Development
• Translational Research
• Precision Medicine
ARISTEM GPS™ – The Biological Navigation Platform™
A novel platform under development exploring how naturally autoguided cellular systems may support disease detection, monitoring and clinical decision-making.
Innovation Through Science
Combining scientific rigor, intellectual property and translational research to advance next-generation biotechnology solutions.
SCIENTIFIC NETWORK & COLLABORATIONS
SCIENTIFIC COLLABORATIONS & ECOSYSTEM
Since its creation in 2013, SCT&B has developed scientific interactions, collaborations and knowledge exchanges with leading organizations active in regenerative medicine, stem cell research, biomarkers and translational medicine.
Organizations associated with our scientific network include:
• Harvard Stem Cell Institute (HSCI)
• National Research Council Canada (NRC)
• CHU de Québec – Université Laval
• École Polytechnique Fédérale de Lausanne (EPFL)
• Héma-Québec
REGULATORY ENVIRONMENT
SCT&B develops its technologies with consideration for internationally recognized regulatory and quality frameworks, including:
• Health Canada
• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Swissmedic
STRATEGIC COLLABORATION AREAS
• Universities and Academic Institutions
• Hospitals and Clinical Centers
• Research Institutes and Laboratories
• Biotechnology and Pharmaceutical Companies
• Precision Medicine Organizations
• Translational Research Networks
NEWS & MILESTONES
Follow the latest developments of SCT&B and ARISTEM GPS™.
2026
ARISTEM GPS™ Investor & Accelerator Program
SCT&B completed the development of ARISTEM GPS™, a biological navigation platform designed to transform invisible disease into actionable clinical information.
The company is actively pursuing institutional validation through academic, clinical and industry partnerships.
2025
ARISTEM GPS™ Intellectual Property Filing
SCT&B strengthened its intellectual property portfolio through the filing of ARISTEM GPS™, a biological navigation platform for precision medicine applications.
2021
Advancement of Biological Navigation Research
Continued development of autoguidance concepts and biological navigation strategies supporting the ARISTEM GPS™ platform.
2013
Creation of SCT&B
Stem Cell Technologies & Biomarkers (SCT&B) was founded to develop innovative technologies in regenerative medicine, biomarkers and translational science.
CURRENT FOCUS
ARISTEM GPS™
The Biological Navigation Platform™
Transforming Invisible Disease Into Actionable Clinical Information.
For partnership inquiries:
WHY IS ARISTEM GPS™ DIFFERENT?
ARISTEM GPS™ is a biological navigation platform developed from years of research into cellular autoguidance and regenerative medicine.
The platform is designed to investigate how naturally occurring cellular systems may recognize and migrate toward pathological tissues through endogenous biological signaling.
Key attributes under investigation include:
• Biological Navigation
• Universal Compatibility Potential
• Non-Engineered Cellular Platform
• Translational Development Potential
• Scalable Manufacturing Strategy
ARISTEM GPS™ aims to contribute to future advances in disease detection, monitoring and precision medicine.
OUR COMMITMENT TO QUALITY
SCT&B is committed to scientific rigor, quality and translational excellence.
Our research and development activities are guided by internationally recognized quality principles and frameworks, including:
• Good Laboratory Practices (GLP)
• Good Clinical Practices (GCP)
• Good Manufacturing Practices (GMP)
Through rigorous science, robust quality systems and responsible innovation, SCT&B advances next-generation biotechnology platforms for precision medicine and future healthcare applications.
Together Advancing Science for Better Health and Better Lives.
Transforming Invisible Disease Into Actionable Clinical Information.